Intergroupe Francophone De Cancerologie Thoracique
Clinical trials sponsored by Intergroupe Francophone De Cancerologie Thoracique, explained in plain language.
-
Could 6 months of treatment match years? lung cancer trial challenges standard practice
Disease control CompletedThis study tested whether stopping immunotherapy after 6 months works as well as continuing it indefinitely for people with advanced lung cancer. Researchers enrolled 265 patients whose cancer had spread and who hadn't received prior treatment. After initial immunotherapy, half c…
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Apr 04, 2026 03:51 UTC
-
Hope for the Too-Sick-for-Trials: new drug tested in frailest lung cancer patients
Disease control CompletedThis study tested the safety and effectiveness of the immunotherapy drug durvalumab in a group of patients often excluded from cancer trials: those with advanced lung cancer who were too frail for standard chemotherapy. It enrolled 50 treatment-naive patients with stage IV non-sm…
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Mar 02, 2026 15:29 UTC